Kras G12D

1 trends tracked about this subject — the full history, oldest to newest below.

▲ Peaking Business

Merck secures exclusive global rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor in a multi-billion dollar agreement.

5 sources 6 articles v 3 2h ago

\n \n \n

\n \n \n \n